Int J Impot Res:根治性前列腺切除术前列腺癌患者中的术前术后睾酮水平研究

2019-01-30 AlexYang MedSci原创

根治性前列腺切除是局部前列腺癌的一种治疗选择。已经报道的数据表明根治性前列腺切除与睾酮水平的增加和减少有关。最近,有研究人员阐释了根治性前列腺切除术前后的血清睾酮水平,以及血清睾酮水平与前列腺情况的相关性。研究包括了85名患有局部和局部晚期前列腺癌且选择根治性前列腺切除术,而之前没有进行雄激素阻断治疗的患者,并搜集了他们的人口统计资料、术前和术后的睾酮水平、性激素结合球蛋白、白蛋白、前列腺特异性抗

根治性前列腺切除是局部前列腺癌的一种治疗选择。已经报道的数据表明根治性前列腺切除与睾酮水平的增加和减少有关。最近,有研究人员阐释了根治性前列腺切除术前后的血清睾酮水平,以及血清睾酮水平与前列腺情况的相关性。

研究包括了85名患有局部和局部晚期前列腺癌且选择根治性前列腺切除术,而之前没有进行雄激素阻断治疗的患者,并搜集了他们的人口统计资料、术前和术后的睾酮水平、性激素结合球蛋白、白蛋白、前列腺特异性抗原和最终的病理报告等数据。研究发现,他们的平均年龄为67.32岁,平均的术前和术后血清睾酮水平分别为424.95ng/dL和371.94ng/dL(p<0.001)。在那些最终病理报告格林森4+3和更高等级的患者与格林森3+3和格林森3+4相比,睾酮减少更大(p=0.001)。研究人员并未观察到术前睾酮水平与最终格林森得分之间的相关性。

最后,研究人员指出,他们的研究表明了根治性前列腺切除术后睾酮水平具有明显的减少,并且高格林森等级患者睾酮水平减少更加显著。他们的发现对预测术后前列腺癌患者性机能状态具有临床应用意义。

原始出处:

Supanut Lumbiganon, Suthep Patcharatrakul, Wisoot Khongcharoensombat et al. Pre- and post-radical prostatectomy testosterone levels in prostate cancer patients. Int J Impot Res. 18 January 2019.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1877116, encodeId=f4be18e7116a2, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Wed Sep 18 00:09:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708844, encodeId=59691e088440c, content=<a href='/topic/show?id=ffca32501e6' target=_blank style='color:#2F92EE;'>#前列腺切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32501, encryptionId=ffca32501e6, topicName=前列腺切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe731571573, createdName=1249898am25暂无昵称, createdTime=Sat Aug 03 10:09:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575099, encodeId=452e15e50995f, content=<a href='/topic/show?id=6f66121e89e' target=_blank style='color:#2F92EE;'>#MPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12178, encryptionId=6f66121e89e, topicName=MPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b9016060451, createdName=风铃826, createdTime=Fri Feb 01 12:09:00 CST 2019, time=2019-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586129, encodeId=4c25158612961, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Fri Feb 01 12:09:00 CST 2019, time=2019-02-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1877116, encodeId=f4be18e7116a2, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Wed Sep 18 00:09:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708844, encodeId=59691e088440c, content=<a href='/topic/show?id=ffca32501e6' target=_blank style='color:#2F92EE;'>#前列腺切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32501, encryptionId=ffca32501e6, topicName=前列腺切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe731571573, createdName=1249898am25暂无昵称, createdTime=Sat Aug 03 10:09:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575099, encodeId=452e15e50995f, content=<a href='/topic/show?id=6f66121e89e' target=_blank style='color:#2F92EE;'>#MPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12178, encryptionId=6f66121e89e, topicName=MPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b9016060451, createdName=风铃826, createdTime=Fri Feb 01 12:09:00 CST 2019, time=2019-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586129, encodeId=4c25158612961, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Fri Feb 01 12:09:00 CST 2019, time=2019-02-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1877116, encodeId=f4be18e7116a2, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Wed Sep 18 00:09:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708844, encodeId=59691e088440c, content=<a href='/topic/show?id=ffca32501e6' target=_blank style='color:#2F92EE;'>#前列腺切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32501, encryptionId=ffca32501e6, topicName=前列腺切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe731571573, createdName=1249898am25暂无昵称, createdTime=Sat Aug 03 10:09:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575099, encodeId=452e15e50995f, content=<a href='/topic/show?id=6f66121e89e' target=_blank style='color:#2F92EE;'>#MPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12178, encryptionId=6f66121e89e, topicName=MPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b9016060451, createdName=风铃826, createdTime=Fri Feb 01 12:09:00 CST 2019, time=2019-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586129, encodeId=4c25158612961, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Fri Feb 01 12:09:00 CST 2019, time=2019-02-01, status=1, ipAttribution=)]
    2019-02-01 风铃826
  4. [GetPortalCommentsPageByObjectIdResponse(id=1877116, encodeId=f4be18e7116a2, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Wed Sep 18 00:09:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708844, encodeId=59691e088440c, content=<a href='/topic/show?id=ffca32501e6' target=_blank style='color:#2F92EE;'>#前列腺切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32501, encryptionId=ffca32501e6, topicName=前列腺切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe731571573, createdName=1249898am25暂无昵称, createdTime=Sat Aug 03 10:09:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575099, encodeId=452e15e50995f, content=<a href='/topic/show?id=6f66121e89e' target=_blank style='color:#2F92EE;'>#MPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12178, encryptionId=6f66121e89e, topicName=MPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b9016060451, createdName=风铃826, createdTime=Fri Feb 01 12:09:00 CST 2019, time=2019-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586129, encodeId=4c25158612961, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Fri Feb 01 12:09:00 CST 2019, time=2019-02-01, status=1, ipAttribution=)]
    2019-02-01 jeanqiuqiu

相关资讯

Scand J Urol:阴性核磁共振成像作用研究

是否具有前列腺癌疑似患者和阴性核磁共振成像(MRI)的患者能够安全地排除活检仍旧不清楚。最近,有研究人员评估了在排除前列腺癌情况下,MRI的临床阴性预测值(NPV)。主要终点为比较NPV来检测MRI显著性前列腺癌。次级结果为比较NPV来检测分类为 PI-RADS1和PI-RADS2的显著性前列腺癌。研究发现,有222(20%)个MRI案例没有靶向成像疑似区域,因此被记录为阴性测试:130(59%)

NEJM:前列腺癌:根治性前列腺切除术vs观望等待

2018年12月,瑞典、英国、芬兰等国学者在《N Engl J Med》发表了前列腺癌患者根治性前列腺切除术或观望等待:29年随访。

Prostate Cancer P D:新系统性治疗对转移去势难治性前列腺癌患者总生存影响研究

2004年,多烯紫杉醇展现出了能够延长转移去势难治性前列腺癌(mCRPC)患者总生存(OS)的效果。自从2010年,已经出现了5中系统性的治疗且能够延长mCRPC患者的OS。最近,有研究人员评估了这些新疗法对mCRPC患者的OS的整体影响。研究包括了2个群体,分别是2004年到2007年间有限药物治疗的群体A和2010年到2013年接受新疗法的群体B。研究发现,与群体A(n=318)比较,接受新疗

盘点2018:前列腺癌治疗新进展

目前已有不少文献显示转移性前列腺癌、高度恶性前列腺癌、致死性前列腺癌往往伴有BRCA2、BRCA1、ATM等DNA修复基因的胚系突变。在新型内分泌治疗药物已占有重要地位的今天,这些胚系突变是否可以预测其疗效还存在争议。

欧盟委员会批准前列腺癌新药Erleada(apalutamide):口服雄激素受体抑制剂

Erleada(apalutamide)已被批准用于治疗转移性疾病高风险的非转移性去势抵抗性前列腺癌(nmCRPC)患者。

Nat Commun:ONECUT2是神经内分泌前列腺癌的驱使因子

神经内分泌前列腺癌(NEPC)是一种致死性的疾病,可以通过雄激素受体(AR)信号在神经内分泌分化过程中的缺失来鉴定。临床上、基因组水平上和表观遗传水平上来讲,NEPC类似于其他类型的低分化程度的神经内分泌肿瘤(NETs)。最近,有研究人员通过pan-NET分析,鉴定了ONECUT2可以作为低分化NETs的候选主要转录调控因子。ONECUT2在前列腺恶性肿瘤中的异位表达能够与缺氧协同来抑制雄激素信号